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Background
Rotavirus is the most common cause of severe gastroenteritis among young children 
worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African 
children.
Methods
We conducted a randomized, placebo-controlled, multicenter trial in South Africa 
(3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to 
evaluate the efficacy of a live, oral rotavirus vaccine in preventing severe rotavirus 
gastroenteritis. Healthy infants were randomly assigned in a 1:1:1 ratio to receive two 
doses of vaccine (in addition to one dose of placebo) or three doses of vaccine — the 
pooled vaccine group — or three doses of placebo at 6, 10, and 14 weeks of age. 
Episodes of gastroenteritis caused by wild-type rotavirus during the first year of life 
were assessed through active follow-up surveillance and were graded with the use 
of the Vesikari scale.
Results
A total of 4939 infants were enrolled and randomly assigned to one of the three 
groups; 1647 infants received two doses of the vaccine, 1651 infants received three 
doses of the vaccine, and 1641 received placebo. Of the 4417 infants included in the 
per-protocol efficacy analysis, severe rotavirus gastroenteritis occurred in 4.9% of 
the infants in the placebo group and in 1.9% of those in the pooled vaccine group 
(vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was 
lower in Malawi than in South Africa (49.4% vs. 76.9%); however, the number of epi-
sodes of severe rotavirus gastroenteritis that were prevented was greater in Malawi 
than in South Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). 
Efficacy against all-cause severe gastroenteritis was 30.2%. At least one serious 
adverse event was reported in 9.7% of the infants in the pooled vaccine group and 
in 11.5% of the infants in the placebo group.
Conclusions
Human rotavirus vaccine significantly reduced the incidence of severe rotavirus 
gastroenteritis among African infants during the first year of life. (ClinicalTrials.gov 
number, NCT00241644.)
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Rotavirus is the most important cause of severe gastroenteritis among chil-dren worldwide. The World Health Organi-
zation (WHO) estimates that globally 527,000 
deaths occur each year among children as a result 
of rotavirus infection1; more than 230,000 of the 
deaths occur in sub-Saharan Africa. Six of the 
seven countries with the highest mortality due to 
rotavirus diarrhea are located in Africa.2 Similarly, 
data generated from global rotavirus surveillance 
networks highlight the burden of hospitalizations 
for rotavirus3; among young children hospitalized 
for acute diarrhea, the median detection rate for 
rotavirus was 40% globally and 41% in Africa. 
Therefore, measures to prevent rotavirus diarrhea 
in African children are urgently needed.
Vaccines represent the best hope for prevent-
ing the severe consequences of rotavirus infec-
tion, especially in impoverished regions where 
resources and access to care may be limited. 
Two oral, live attenuated rotavirus vaccines, Ro-
tarix (GlaxoSmithKline Biologicals) and RotaTeq 
(Merck), have shown excellent protective efficacy 
against severe rotavirus gastroenteritis in trials 
conducted mainly in Latin America, Europe, and 
the United States.4-6 The WHO’s Strategic Advi-
sory Group of Experts (SAGE) first reviewed data 
on these vaccines in 2005 and strongly recom-
mended the inclusion of rotavirus vaccination in 
the national immunization programs of countries 
and regions in which, according to available data, 
severe rotavirus gastroenteritis has a substantial 
public health impact.7 But SAGE noted that live 
oral vaccines may not be as effective in protecting 
the poorest children in developing countries as 
they are in protecting children in industrialized 
countries and therefore recommended that effi-
cacy trials be conducted in representative popula-
tions in Africa and Asia before the recommenda-
tion is extended.1,7 In response to this mandate, 
we conducted a clinical trial to determine whether 
Rotarix, an attenuated human rota virus vaccine 
containing a G1P[8] strain, could protect African 
children against severe rotavirus gastroenteritis.
Me thods
Study Design and Participants
We conducted a double-blind, randomized, pla-
cebo-controlled multicenter study in South Africa 
and Malawi to assess the efficacy, safety, and im-
munogenicity of Rotarix. A placebo-controlled 
design was chosen because the vaccine was not 
licensed or available in these countries at the 
time the study was initiated, and data were needed 
to inform policy decisions in low-resource coun-
tries. Children who were infected with human 
immunodeficiency virus (HIV) and children who 
had been exposed to HIV were included in the 
trial on the basis of the absence of serious immu-
nosuppression in infants at the age at which 
these vaccines are first given (6 weeks), the experi-
ence with other live vaccines in HIV-infected chil-
dren, and the need to inform decisions on the 
introduction of vaccine in settings with high prev-
alences of HIV. The study protocol and the in-
formed consent form were approved by the ethics 
committee at the WHO and by the ethics com-
mittees at all study centers. The trial was conduct-
ed in accordance with Good Clinical Practice 
guidelines. The parents or legal representatives 
of the infants participating in the study provided 
written informed consent before the initiation of 
any study-related procedures. All the investiga-
tors shared responsibility for the design of the 
study and the accrual and analysis of the data. All 
the authors participated in the preparation of the 
manuscript and made the decision to submit the 
manuscript for publication.
In South Africa, healthy infants, 5 to 10 weeks 
of age, were enrolled from October 2005 through 
January 2006 and from November 2006 through 
early February 2007, before the anticipated ro-
tavirus seasons of 2006 and 2007, respectively.8,9 
Since rotavirus is known to circulate year-round 
in Malawi,10 infants in Malawi were enrolled 
from October 2006 through July 2007.
Infants were randomly assigned individually, 
in a 1:1:1 ratio, into three groups to receive two 
doses of the rotavirus vaccine at 10 and 14 weeks 
of age; three doses of the vaccine at 6, 10, and 
14 weeks of age; or three doses of placebo. Infants 
in the two-dose vaccine group received a dose of 
placebo at 6 weeks of age. Vaccines that are ad-
ministered routinely according to the guidelines 
of the Expanded Program on Immunization (EPI) 
were concomitantly administered with the vac-
cine or placebo. No restrictions were imposed on 
the breast-feeding of infants around the time of 
vaccination.
Testing for HIV
The parents or legal representatives of the infants 
were given the opportunity to have the infants 
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tested for HIV at the time the first dose of vaccine 
or placebo was administered or 1 month after the 
last dose, and testing was performed when con-
sent was given. Detailed information regarding 
the testing and treatment of infants is included 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org.
Vaccine
The study vaccine, the calcium carbonate buffer, 
and the placebo were developed and manufac-
tured by GlaxoSmithKline Biologicals. The com-
position of the vaccine was the same as the com-
mercial formulation, and the placebo was the 
same formulation without the viral antigen.11
Analysis of Stool Samples during Episodes  
of Gastroenteritis
An episode of gastroenteritis was identified by the 
occurrence of diarrhea, whether or not it was ac-
companied by vomiting; diarrhea was defined as 
the passage of three or more stools that were 
looser than normal within a 24-hour period. Stool 
samples were collected during each episode of 
gastroenteritis that occurred between the date the 
first dose of vaccine or placebo was administered 
and the date the child reached 1 year of age. Stool 
samples were tested for rotavirus with the use of 
an enzyme-linked immunosorbent assay (ELISA) 
(Rotaclone, Meridian Bioscience). All stool sam-
ples that were positive for rotavirus were examined 
further with the use of a reverse-transcriptase–
polymerase-chain-reaction (PCR) assay, followed 
by a reverse hybridization assay to determine the 
G and P types.12
Assessment of Vaccine Efficacy
The efficacy of the vaccine was assessed during 
the period from 2 weeks after the last dose of 
vaccine or placebo was administered until the 
child reached 1 year of age. Active surveillance 
for all gastroenteritis episodes was conducted by 
members of the study staff through weekly visits 
to parents or guardians to collect diary cards and 
through the collection of data from health clinics 
that served the study populations. The severity of 
each episode of gastroenteritis was evaluated with 
the use of the Vesikari scale13 (on which scores 
range from 1 to 20, with higher scores indicating 
greater severity) and was categorized as severe if 
the score was 11 or more.
Assessment of Safety
All serious adverse events including deaths were 
recorded for the period between the date the first 
dose of vaccine or placebo was administered and 
the date the child reached 1 year of age. The site 
investigator, who was unaware of the group as-
signments of the children, determined whether 
the serious adverse events appeared to have any 
causal association with vaccination.
Assessment of Immunogenicity
Blood samples were collected from approximate-
ly 10% of the infants immediately before the first 
dose of vaccine or placebo was administered and 
from all infants 1 month after the last dose to 
determine the serum concentrations of antirota-
virus IgA antibody. The blood samples were ana-
lyzed with the use of an ELISA (GlaxoSmithKline 
Biologicals), with the assay cutoff point set at 20 U 
per milliliter.14
Statistical Analysis
The primary study analysis compared findings 
from the pooled vaccine group with those from 
the placebo group. The secondary end points were 
the efficacy of each vaccine dose (i.e., the two-
dose vaccine and the three-dose vaccine) as com-
pared with placebo. A supplementary analysis 
was performed to evaluate the efficacy, immuno-
genicity, and safety of the vaccine according to 
country.
Infants who had received the complete vacci-
nation course and had entered the efficacy sur-
veillance period, which began 2 weeks after the 
last dose, were included in the prespecified pri-
mary efficacy analysis (per-protocol efficacy co-
hort). Infants in the pooled vaccine and placebo 
groups who had at least one episode of severe 
rotavirus gastroenteritis caused by wild-type rota-
virus strains during the period from 2 weeks 
after the last dose was administered until the 
infants reached 1 year of age were considered as 
having achieved the primary outcome. The effi-
cacy analysis was also performed on data from 
the total cohort, which included infants who re-
ceived at least one dose of vaccine or placebo. The 
safety analysis was performed on data from the 
total cohort. The immunogenicity analysis was 
performed on data from infants in the per-proto-
col efficacy cohort for whom immunogenicity 
data were available. The method used to calculate 
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the sample size and specific information about 
the statistical analysis are shown in the Supple-
mentary Appendix.
R esult s
Study Population
A total of 4939 infants were enrolled and ran-
domly assigned to one of three groups (Fig. 1); 
1647 infants were assigned to the two-dose 
group, 1651 to the three-dose group (for a total 
of 3298 in pooled vaccine group), and 1641 to 
the placebo group. A total of 4417 infants were 
included in the primary efficacy analysis — 2974 
in the pooled vaccine group and 1443 in the pla-
cebo group. The reasons for withdrawal from 
the study are listed in Figure 1. The demograph-
ic characteristics of the infants and the propor-
tion of children who were infected with HIV were 
similar across the study groups. Almost all in-
fants (≥99%) received oral poliovirus vaccine 
concomitantly with each dose of rotavirus vac-
cine or placebo (Table 1 in the Supplementary 
Appendix).
7 col
39p6
4939 (99.9%) Underwent randomization
and were included in the safety analysis
4941 Infants were assessed for eligibility
2 Withdrew consent
3298 Were assigned to receive
rotavirus vaccine
1641 Were assigned to receive
placebo
495 Were withdrawn
90 Had a serious adverse event
1 Had a nonserious adverse event
8 Had a protocol violation
133 Withdrew consent (not owing to
adverse event)
115 Relocated
143 Were lost to follow-up
62 Had incomplete vaccination course
81 Had complete vaccination course
5 Had other reasons
249 Were withdrawn
44 Had a serious adverse event
1 Had a nonserious adverse event
4 Had a protocol violation
79 Withdrew consent (not owing to
adverse event)
53 Relocated
63 Were lost to follow-up
29 Had incomplete vaccination course
34 Had complete vaccination course
5 Had other reasons
324 Were excluded from the efficacy analysis
264 Were not administered at least one
dose
23 Contracted concomitant infection by
rotavirus strain other than the vaccine
strain up to 2 wk after dose 3 (which
may influence efficacy response)
21 Were not administered study vaccine
dose as per protocol
11 Were not entered into the follow-up
surveillance period
5 Had broken randomization code
198 Were excluded from the efficacy analysis
140 Were not administered at least one
dose
39 Contracted concomitant infection by
rotavirus strain other than the vaccine
strain up to 2 wk after dose 3 (which
may influence efficacy response)
8 Were not administered study vaccine
dose as per protocol
10 Were not entered into the follow-up
surveillance period
1 Had broken randomization code
2974 (90.1%) Were included in the
efficacy analysis
1443 (87.9%) Were included in the
efficacy analysis
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Figure 1. Study Assignment and Follow-up.
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Efficacy
Severe gastroenteritis caused by circulating rota-
virus was detected in 70 of 1443 infants in the 
placebo group (4.9%) as compared with 56 of 
2974 infants in the pooled vaccine group (1.9%), 
resulting in a vaccine efficacy against the primary 
outcome of severe rotavirus gastroenteritis of 
61.2% (95% confidence interval [CI], 44.0 to 73.2; 
P<0.001) (Table 1). Vaccination with the rotavirus 
vaccine prevented 5.0 episodes of severe rotavirus 
gastroenteritis per 100 infant-years (Table 2). The 
vaccine showed efficacy against severe rotavirus 
gastroenteritis both in infants who received two 
doses of vaccine (58.7% efficacy; 95% CI, 35.7 to 
74.0) and in those who received three doses (63.7% 
efficacy; 95% CI, 42.4 to 77.8). In South Africa, 
the efficacy of the vaccine was 76.9% (95% CI, 
56.0 to 88.4), and in Malawi the vaccine efficacy 
was 49.4% (95% CI, 19.2 to 68.3); 4.2 and 6.7 epi-
sodes of severe rotavirus gastroenteritis per 100 
infant-years were prevented by vaccination in South 
Africa and Malawi, respectively (Tables 1 and 2). 
The efficacy of the rotavirus vaccine against ro-
tavirus gastroenteritis of any severity is presented 
in Table 2 in the Supplementary Appendix.
The distribution of rotavirus G and P types 
Table 1. Efficacy of Rotavirus Vaccine with Respect to the Development of Severe Rotavirus Gastroenteritis and Hospitalization for Rotavirus 
Gastroenteritis.*
Variable Infants with at Least One Event Vaccine Efficacy P Value†
Rotavirus Vaccine Placebo
no./total no.  % (95% CI) no./total no. % (95% CI) % (95% CI)
Severe rotavirus gastroenteritis
Overall
Pooled 56/2974 1.9 (1.4–2.4) 70/1443 4.9 (3.8–6.1) 61.2 (44.0–73.2) <0.001
Two-dose 30/1496 2.0 (1.4–2.9) — — 58.7 (35.7–74.0) <0.001
Three-dose 26/1478 1.8 (1.2–2.6) — — 63.7 (42.4–77.8) <0.001
Malawi
Pooled 41/1030 4.0 (2.9–5.4) 38/483 7.9 (5.6–10.6) 49.4 (19.2–68.3) 0.003
Two-dose 21/525 4.0 (2.5–6.0) — — 49.2 (11.1–71.7) 0.01
Three-dose 20/505 4.0 (2.4–6.1) — — 49.7 (11.3–72.2) 0.01
South Africa
Pooled 15/1944 0.8 (0.4–1.3) 32/960 3.3 (2.3–4.7) 76.9 (56.0–88.4) <0.001
Two-dose 9/971 0.9 (0.4–1.8) — — 72.2 (40.4–88.3) <0.001
Three-dose 6/973 0.6 (0.2–1.3) — — 81.5 (55.1–93.7) <0.001
Rotavirus-type–specific severe rota - 
virus gastroenteritis‡
Overall
G1 strain 17/2974 0.6 (0.3–0.9) 23/1443 1.6 (1.0–2.4) 64.1 (29.9–82.0) 0.002
Non-G1 strain 39/2974 1.3 (0.9–1.8) 47/1443 3.3 (2.4–4.3) 59.7 (37.1–74.4) <0.001
Malawi
G1 strain 6/1030 0.6 (0.2–1.3) 5/483 1.0 (0.3–2.4) 43.7 (<0–85.7) 0.34
Non-G1 strain 35/1030 3.4 (2.4–4.7) 33/483 6.8 (4.7–9.5) 50.3 (17.4–70.0) 0.005
South Africa
G1 strain 11/1944 0.6 (0.3–1.0) 18/960 1.9 (1.1–2.9) 69.8 (32.5–87.1) 0.002
Non-G1 strain 4/1944 0.2 (0.1–0.5) 14/960 1.5 (0.8–2.4) 85.9 (55.1–96.6) <0.001
Hospitalization for rotavirus  
gastroenteritis‡
14/2974 0.5 (0.3–0.8) 16/1443 1.1 (0.6–1.8) 57.5 (7.2–80.8) 0.02
* A total of 4417 infants were included in the efficacy analysis — 2974 in the pooled vaccine group and 1443 in the placebo group.
† P values were calculated with the use of a two-sided Fisher’s exact test. P values of less than 0.05 were considered to indicate a statistically 
significant difference.
‡ Data in the rotavirus vaccine group are for the pooled vaccine cohort.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 13, 2014. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 362;4 nejm.org january 28, 2010294
differed between South Africa and Malawi (Fig. 1 
in the Supplementary Appendix). The G1P[8] strain 
was detected in 57.0% of the episodes among 
recipients of the placebo in South Africa and in 
12.9% of the episodes among recipients of the 
placebo in Malawi. The type-specific efficacy 
against severe rotavirus gastroenteritis and the 
difference in incidence rates between the vaccine 
groups and the placebo group are shown in Ta-
ble 1 and Table 2, respectively.
The incidence rate of severe gastroenteritis 
from any cause was 8.6% in the pooled vaccine 
group as compared with 12.3% in the placebo 
group, corresponding to a reduction in the rate 
with vaccination of 30.2% (95% CI, 15.0 to 42.6; 
P<0.001) (Table 3). The reductions in all-cause 
severe gastroenteritis were statistically signifi-
cant in both countries. The efficacy of the vac-
cine in the total vaccinated cohort was similar to 
that in the per-protocol efficacy cohort (Tables 
3 to 6 in the Supplementary Appendix).
Safety
At least one serious adverse event occurred dur-
ing the study period in 319 of the 3298 infants in 
the pooled vaccine group (9.7%; 95% CI, 8.7 to 
10.7) and in 189 of the 1641 infants in the pla-
cebo group (11.5%; 95% CI, 10.0 to 13.2) (Table 
7 in the Supplementary Appendix). During the 
entire study period, 83 deaths occurred among 
infants in the pooled vaccine group (2.5%; 95% 
CI, 2.0 to 3.1) and 43 deaths occurred among 
those in the placebo group (2.6%; 95% CI, 1.9 to 
3.5). A single case of intussusception occurred 11 
weeks after the third dose of rotavirus vaccine in 
a 6-month-old child who was assigned to the 
three-dose vaccine group. The child underwent 
bowel resection and recovered fully. Three adverse 
Table 2. Risk of Severe Rotavirus Gastroenteritis in the Pooled Vaccine Group and the Placebo Group, According to 
Dose, Country, and Rotavirus Strain.*
Cohort Rotavirus Vaccine Placebo
Difference in Rate
(95% CI)†
No. in  
Cohort
Episodes/ 
100 Infants/Yr
(95% CI)
No. in  
Cohort
Episodes/ 
100 Infants/Yr
(95% CI)
Severe rotavirus gastroenteritis
Pooled 2974 3.0 (2.3–3.9) 1443 8.0 (6.3–10.1) 5.0 (3.1–7.2)
Two-dose 1496 3.2 (2.2–4.6) — — 4.8 (2.6–7.1)
Three-dose 1478 2.8 (1.9–4.1) — — 5.2 (3.0–7.5)
Country‡
Malawi 1030 6.5 (4.8–8.8) 483 13.1 (9.6–18.0) 6.7 (2.4–11.9)
South Africa 1944 1.2 (0.7–2.0) 960 5.4 (3.8–7.7) 4.2 (2.4–6.5)
Rotavirus type‡
Total cohort 2974 1443
G1 strain 0.9 (0.6–1.5) 2.6 (1.7–3.9) 1.7 (0.6–3.0)
Non-G1 strain 2.1 (1.5–2.9) 5.3 (4.0–7.1) 3.2 (1.7–5.1)
Malawi 1030 483
G1 strain 0.9 (0.4–2.1) 1.7 (0.7–4.0) 0.7 (<0–3.1)
Non-G1 strain 5.5 (4.0–7.7) 11.3 (8.1–16.0) 5.8 (1.9–10.7)
South Africa 1944 960
G1 strain 0.9 (0.5–1.6) 3.0 (1.9–4.8) 2.1 (0.8–3.9)
Non-G1 strain 0.3 (0.1–0.9) 2.4 (1.4–4.0) 2.0 (0.9–3.7)
* The analyses are based on the efficacy cohort, which comprised 4417 infants — 2974 in the pooled vaccine group and 
1443 in the placebo group.
† The difference in rate is calculated as the episodes per 100 infants per year in the placebo group minus the episodes 
per 100 infants per year in the rotavirus vaccine group.
‡ Data in the rotavirus vaccine group are for the pooled vaccine cohort.
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events were judged by the investigators to be re-
lated to vaccination — two cases of sepsis and 
one of otitis media.
Immunogenicity
At 1 month after the last dose of vaccine was 
administered, the seroconversion rates for anti-
rotavirus IgA in South Africa were 57.1% (95% 
CI, 44.7 to 68.9) in the two-dose group and 66.7% 
(95% CI, 54.0 to 77.8) in the three-dose group. 
The seroconversion rates in Malawi were 47.2% 
(95% CI, 30.4 to 64.5) in the two-dose group and 
57.1% (95% CI, 42.2 to 71.2) in the three-dose 
group. In the placebo group, the seropositivity 
rates for antirotavirus IgA at 1 month after the 
last dose were 16.7% (95% CI, 14.2 to 19.5) in 
South Africa and 40.4% (95% CI, 34.9 to 46.1) in 
Malawi.
DISCUSSION
This study shows that a live, oral rotavirus vac-
cine significantly reduces the episodes of severe 
rotavirus gastroenteritis in African children dur-
ing the first year of life. The attack rate for severe 
rotavirus gastroenteritis was higher in these pop-
ulations than has been reported in other studies 
of rotavirus vaccines.4,5 Because of this high inci-
dence of severe disease, a vaccine efficacy of 61.2% 
resulted in a substantial vaccine-attributable re-
duction in severe rotavirus gastroenteritis (reduc-
tion of 5.0 cases per 100 infant-years). In addition, 
the rotavirus vaccine was associated with a reduc-
tion in all-cause severe gastroenteritis of 30.2%. 
This reduction in the incidence of the disease oc-
curred in a trial that was designed to simulate 
real-world conditions of use; thus, the rotavirus 
vaccine is expected to deliver a considerable pub-
lic health benefit when it is introduced into sim-
ilar settings.
The overall efficacy of the rotavirus vaccine in 
preventing episodes of severe rotavirus gastroen-
teritis (61.2%) was lower than that observed in 
European studies and Latin American studies 
(96.4% and 84.8%, respectively), which included 
some low- to middle-income countries.4-6,15 This 
finding is consistent with findings from other 
studies of live oral vaccines, such as the oral 
poliovirus vaccine,16 the cholera vaccine,17 oral ty-
phoid vaccines,18 and earlier rotavirus vaccines,19 
none of which were as immunogenic or effective 
in populations in developing countries as they 
were in populations in industrialized countries. 
Several mechanisms have been proposed to ex-
plain why live oral rotavirus vaccines may not be 
as efficacious in populations of infants from low-
income countries.20 Possible reasons include host 
characteristics, such as poor nutritional status 
and enteric coinfections; levels of antirotavirus 
antibodies in breast milk; and interference by 
maternal antibody or by coadministration of the 
oral poliovirus vaccine, which may reduce rota-
virus antibody levels.21,22 The potential role of 
these and other factors will be important to elu-
cidate, in order to further improve the perfor-
mance of these vaccines in populations where 
they are most needed.
The efficacy of the rotavirus vaccine in Mala-
wian infants in this study was lower than that in 
their South African counterparts (49.4% vs. 
76.9%). In addition to potential differences men-
tioned above, rotavirus circulation differs in the 
two countries (a winter–spring peak in South 
Africa8,9 as compared with year-round circulation 
in Malawi10), and that difference was reflected in 
the study enrollment strategies (preceding the 
Table 3. Efficacy of Rotavirus Vaccine against All-Cause Severe Gastroenteritis.*
Cohort Infants with at Least One Event of All-Cause Severe Gastroenteritis Vaccine Efficacy P Value†
Rotavirus Vaccine Placebo
no./total no. % (95% CI) no./total no. % (95% CI) % (95% CI)
Overall 256/2974 8.6 (7.6–9.7) 178/1443 12.3 (10.7–14.1) 30.2 (15.0–42.6) <0.001
Malawi 187/1030 18.2 (15.8–20.6) 117/483 24.2 (20.5–28.3) 25.1 (4.7–40.8) 0.007
South Africa 69/1944 3.5 (2.8–4.5) 61/960 6.4 (4.9–8.1) 44.1 (19.8–61.0) <0.001
* The analyses are based on the efficacy cohort, which comprised 4417 infants — 2974 in the pooled vaccine group and 
1443 in the placebo group.
† P values were calculated with the use of a two-sided Fisher’s exact test. P values of less than 0.05 were considered to 
indicate a statistically significant difference.
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rotavirus season in South Africa as compared 
with year-round in Malawi). The rotavirus sero-
positivity rate among placebo recipients 1 month 
after the last dose had been given was greater 
among Malawian infants than among South Afri-
can infants (40.4% vs. 16.7%), suggesting that 
Malawian infants have high exposure to wild-
type rotavirus infection in the first 5 months of 
life. Since infection with wild-type rotavirus con-
fers protection against the development of severe 
rotavirus disease later in infancy,23 the greater 
exposure of the infants in the placebo group in 
Malawi to rotavirus infection before their entry 
into the follow-up period may have lowered the 
estimate of vaccine efficacy in Malawi. Despite 
the lower point estimate for efficacy, the number 
of severe cases of rotavirus gastroenteritis pre-
vented was greater in Malawi than in South Africa 
(6.7 vs. 4.2 cases prevented per 100 infant-years), 
owing to the higher incidence of severe rotavirus 
gastroenteritis in Malawi.
In this study, the diversity of the circulating 
strains was striking. In Malawi, only 12.9% of 
the rotavirus strains were G1P[8] — the strain 
on which this vaccine is based, and the most 
commonly occurring strain globally.24,25 A sub-
stantial proportion of G2, G8, G9, and G12 
strains were isolated during the course of this 
study. Rotavirus types G2, G8, and G9 have cir-
culated for several years in both countries, where-
as rotavirus type G12 has been reported more 
recently.26,27 It is unlikely, however, that these 
differences in strains contributed to the lower 
vaccine efficacy, since the efficacy against G1 
and non-G1 severe rotavirus gastroenteritis was 
similar. These data are consistent with an inte-
grated analysis of previous efficacy trials of the 
rota virus vaccine, which indicates that the rota-
virus vaccine provides protection against severe 
rotavirus gastroenteritis caused by G1 and non-
G1 strains.28 The ability of a rotavirus vaccine to 
protect against a wide panel of strains is impor-
tant in Africa, where the diversity of rotavirus 
strains is substantial.24,25,29
We did not detect significant differences in 
vaccine immunogenicity or efficacy between the 
cohort receiving two vaccine doses and the co-
hort receiving three doses, although this study 
was not powered to detect such differences. There 
was a slight but nonsignificant trend toward 
higher seroconversion rates and vaccine efficacy 
with the three-dose schedule. It should be noted 
that in the two-dose schedule used in this study, 
the doses of vaccine were administered at the 
second and third childhood vaccine visit, when 
the infants were an average of 11 and 16 weeks 
of age, respectively. Outside the setting of a clini-
cal trial, a two-dose schedule in which the rota-
virus vaccine is administered at the second and 
third childhood vaccination visits is not practi-
cal, since it is recommended that the first dose 
of rotavirus vaccine be delivered before the infant 
is 12 weeks of age, owing to lingering concerns 
stemming from the age-dependent risk of intus-
susception associated with a previous rotavirus 
vaccine.1 Since children in developing countries 
frequently present late for vaccination visits,30 this 
age restriction would deny many children the 
opportunity to receive the rotavirus vaccine if it 
were recommended at a later visit. Although a 
two-dose schedule in which the vaccine is admin-
istered at the first and second childhood vaccina-
tion visits is a more practical option, such a 
schedule was not tested in this study. Adminis-
tering rotavirus vaccines at younger ages could 
lower the immunogenicity of the vaccines, be-
cause of the potential for greater interference of 
maternal antibody20 and enhanced replication of 
the oral poliovirus vaccine.22,31,32 It will be impor-
tant to undertake studies to assess the effective-
ness of two doses of rotavirus vaccine adminis-
tered at earlier ages than those at which they 
were administered in this study.
The WHO’s Global Advisory Committee on 
Vaccine Safety (GACVS) has reviewed the safety of 
the currently licensed rotavirus vaccines33,34 and 
has concluded that in clinical trials of these vac-
cines, no association was seen between receipt of 
the vaccines and an increased risk of intussus-
ception. Further, postmarketing surveillance data 
show that an intussusception risk that is of a 
similar magnitude to that which had been as-
sociated with a previous rotavirus vaccine, Rota-
shield (Wyeth–Lederle), is unlikely.34,35 The single 
case of intussusception in this trial was not tem-
porally related to rotavirus vaccination, and the 
rate of serious adverse events did not differ be-
tween infants who received the vaccine and those 
who received the placebo. Continuing surveillance 
of the safety of the vaccines as they are intro-
duced into more countries will be important.
On the basis of this study and other support-
ing data, SAGE recently recommended that rota-
virus vaccination of infants be included in all na-
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tional immunization programs, in conjunction 
with other proven interventions for diarrheal dis-
ease.36 Appropriate financing mechanisms that 
will allow ministries of health in Africa to bring 
this potentially lifesaving vaccine to the children 
in greatest need are urgently needed.
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